Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score–matched analysis
Brett L. Ecker(Rutgers, The State University of New Jersey), Robert E. Roses(University of Pennsylvania), Daniel T. Dempsey(University of Pennsylvania), Giorgos C. Karakousis(Hospital of the University of Pennsylvania), Ronac Mamtani(Hospital of the University of Pennsylvania), Matthew T. McMillan(Memorial Sloan Kettering Cancer Center), Jeffrey A. Drebin(Memorial Sloan Kettering Cancer Center), Jashodeep Datta(University of Miami), Bruce J. Giantonio(Northwestern University), Douglas L. Fraker(University of Pennsylvania)
Cited by 115
Related Papers
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
|Nature Medicine|2019|521
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
|Nature Communications|2015|484
Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer
|Clinical Cancer Research|2021|358